Group 1 - The core viewpoint of the news is that Baiotai's stock price has shown fluctuations, with a current price of 25.24 CNY per share and a market capitalization of 10.451 billion CNY [1] - Baiotai's stock has increased by 9.08% since the beginning of the year, with a 2.60% rise in the last five trading days and a 9.93% increase over the last 20 days, while it has decreased by 5.64% over the last 60 days [2] - The company, established on July 28, 2003, focuses on the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [2] Group 2 - As of September 30, 2025, Baiotai reported a revenue of 684 million CNY, representing a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million CNY, showing a year-on-year increase of 38.72% [2] - The company is categorized under the pharmaceutical and biological industry, specifically in the bioproducts sector, and is involved in concepts such as biomedicine and innovative drugs [2] - As of September 30, 2025, the number of shareholders decreased by 0.89% to 9,397, with an average of 44,065 circulating shares per person, which increased by 0.89% [2]

Group 1 - The core viewpoint of the news is that Baiotai's stock has shown a significant increase in price and trading activity, indicating positive market sentiment despite some fluctuations in recent months [1][2]. - As of January 9, Baiotai's stock price rose by 2.03% to 25.08 CNY per share, with a total market capitalization of 10.385 billion CNY [1]. - The company has experienced an 8.38% increase in stock price year-to-date, with a 5.82% increase over the past 20 days, although it has seen a 7.11% decline over the last 60 days [2]. Group 2 - Baiotai's main business involves the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [2]. - As of September 30, 2025, Baiotai reported a revenue of 684 million CNY, reflecting a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million CNY, showing a 38.72% increase in losses compared to the previous year [2]. - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the bioproducts sector, and is involved in various concepts such as biomedicine and cancer treatment [2].

数据显示，鹏华基金旗下1只基金重仓百奥泰。鹏华安泽混合A（009096）三季度持有股数600股，占基 金净值比例为0.02%，位居第十大重仓股。根据测算，今日浮盈赚取约708元。 12月23日，百奥泰涨5.09%，截至发稿，报24.34元/股，成交3410.28万元，换手率0.35%，总市值100.79 亿元。 资料显示，百奥泰生物制药股份有限公司位于广东省广州市国际生物岛螺旋二路18号，成立日期2003年 7月28日，上市日期2020年2月21日，公司主营业务涉及从事创新药和生物类似药的研发、生产业务。主 营业务收入构成为：药品销售业务91.90%，授权许可业务6.55%，代加工业务0.90%，技术服务业务 0.65%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 鹏华安泽混合A（009096）成立日期2020年3月25日，最新规模1330.6万。今年以来收益2.56%，同类排 名7347/8088；近一年收益2.57%，同类排名7290/80 ...

Core Viewpoint - The stock of Baiotai has experienced a decline recently, with a notable drop in trading volume and a significant outflow of funds, despite a year-to-date increase in stock price [1][2]. Group 1: Stock Performance - Baiotai's stock price decreased by 2.01% to 24.35 CNY per share, with a trading volume of 22.72 million CNY and a turnover rate of 0.22% [1]. - Year-to-date, Baiotai's stock has risen by 25.64%, but it has seen a decline of 2.60% over the last five trading days, 8.25% over the last 20 days, and 29.87% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Baiotai achieved a revenue of 684 million CNY, representing a year-on-year growth of 17.57% [2]. - The net profit attributable to the parent company was -224 million CNY, showing a year-on-year increase of 38.72% [2]. Group 3: Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its stock listed on February 21, 2020 [2]. - The company's main business involves the research and production of innovative drugs and biosimilars, with revenue composition as follows: 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2]. Group 4: Shareholder Information - As of September 30, 2025, Baiotai had 9,397 shareholders, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per shareholder, an increase of 0.89% [2]. - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.0247 million shares as a new shareholder [2].

Group 1 - The core viewpoint of the news is that Baiotai's stock has experienced fluctuations, with a current price of 24.77 CNY per share, reflecting a year-to-date increase of 27.81% but a decline of 20.02% over the past 60 days [1] - As of November 28, Baiotai's market capitalization stands at 10.257 billion CNY, with a trading volume of 20.3261 million CNY and a turnover rate of 0.20% [1] - The company primarily engages in the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [1] Group 2 - As of September 30, 2025, Baiotai reported a revenue of 684 million CNY, marking a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million CNY, reflecting a 38.72% increase in losses [2] - The number of shareholders decreased by 0.89% to 9,397, while the average circulating shares per person increased by 0.89% to 44,065 shares [2] - The company is categorized under the pharmaceutical and biological industry, specifically in the bioproducts sector, and is involved in concepts such as innovative drugs and cancer treatment [1]

百奥泰所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、抗癌治癌、 抗癌药物、生物医药、融资融券等。 截至9月30日，百奥泰股东户数9397.00，较上期减少0.89%；人均流通股44065股，较上期增加0.89%。 2025年1月-9月，百奥泰实现营业收入6.84亿元，同比增长17.57%；归母净利润-2.24亿元，同比增长 38.72%。 11月25日，百奥泰盘中上涨2.15%，截至09:39，报25.63元/股，成交603.33万元，换手率0.06%，总市值 106.13亿元。 资金流向方面，主力资金净流出49.39万元，大单买入49.37万元，占比8.18%，卖出98.75万元，占比 16.37%。 百奥泰今年以来股价涨32.25%，近5个交易日跌1.65%，近20日跌6.43%，近60日跌21.60%。 资料显示，百奥泰生物制药股份有限公司位于广东省广州市国际生物岛螺旋二路18号，成立日期2003年 7月28日，上市日期2020年2月21日，公司主营业务涉及从事创新药和生物类似药的研发、生产业务。主 营业务收入构成为：药品销售业务91.90%，授权许可业务6.55%，代加工 ...

Core Viewpoint - Baiotai's stock price has shown a year-to-date increase of 34.93%, but recent trading indicates a decline in the short term, with a notable drop of 21.45% over the past 60 days [2] Company Overview - Baiotai Biopharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on July 28, 2003, with its listing date on February 21, 2020 [2] - The company focuses on the research and production of innovative drugs and biosimilars, with its main business revenue composition being: 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2] Financial Performance - For the period from January to September 2025, Baiotai achieved an operating income of 684 million yuan, representing a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million yuan, reflecting a year-on-year increase of 38.72% [2] Stock Market Activity - As of November 17, Baiotai's stock price was 26.15 yuan per share, with a trading volume of 13.01 million yuan and a turnover rate of 0.12%, resulting in a total market capitalization of 10.828 billion yuan [1] - The net outflow of main funds was 120,900 yuan, with large single purchases amounting to 588,900 yuan (4.53% of total) and sales of 709,800 yuan (5.45% of total) [1] Shareholder Information - As of September 30, 2025, the number of Baiotai's shareholders was 9,397, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per person, an increase of 0.89% [2] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 6.0247 million shares as a new shareholder [2]

Group 1 - The core viewpoint of the news is that Baiotai Biopharmaceutical Co., Ltd. has seen a stock price increase of 5.38%, reaching 27.80 yuan per share, with a total market capitalization of 11.511 billion yuan [1] - Baiotai's main business involves the research and development, production of innovative drugs and biosimilars, with the revenue composition being 91.90% from drug sales, 6.55% from licensing, 0.90% from processing, and 0.65% from technical services [1] Group 2 - From the perspective of fund holdings, Penghua Fund has a significant position in Baiotai, with the Penghua Anze Mixed A fund holding 600 shares, accounting for 0.02% of the fund's net value [2] - The Penghua Anze Mixed A fund has a total scale of 13.306 million yuan and has achieved a year-to-date return of 2.53% [2] Group 3 - The fund managers of Penghua Anze Mixed A include Zhu Song, Zhang Jingxian, and Shi Yunchao, with Zhu Song having a tenure of 11 years and 255 days, managing assets totaling 27.86 billion yuan [3] - The best fund return during Zhu Song's tenure is 106.13%, while the worst is 0.86% [3]

Core Viewpoint - Baiotai's stock price has shown significant fluctuations in 2023, with a year-to-date increase of 61.92% and a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - As of September 18, Baiotai's stock price rose by 2.02% to 31.38 CNY per share, with a total market capitalization of 12.994 billion CNY [1]. - The stock has experienced a 1.16% increase over the last five trading days, a 5.74% decrease over the last 20 days, and a 27.41% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Baiotai reported a revenue of 442 million CNY, reflecting a year-on-year growth of 9.84% [2]. - The company recorded a net profit attributable to shareholders of -125 million CNY, which is a 47.25% improvement compared to the previous year [2]. Group 3: Company Overview - Baiotai Biopharmaceutical Co., Ltd. was established on July 28, 2003, and went public on February 21, 2020 [1]. - The company's main business activities include the research and production of innovative drugs and biosimilars, with 91.90% of revenue coming from drug sales [1].

Group 1 - The core viewpoint of the news is that Baiotai's stock has experienced significant price movements and financial performance indicators, reflecting both market interest and operational results [1][2]. - Baiotai's stock price has increased by 75.49% year-to-date, with a 6.25% rise in the last five trading days, 9.96% in the last 20 days, and 19.00% in the last 60 days [2]. - As of September 2, Baiotai's stock was trading at 34.01 CNY per share, with a total market capitalization of 14.083 billion CNY [1]. Group 2 - Baiotai's main business revenue composition includes 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2]. - The company reported a revenue of 442 million CNY for the first half of 2025, representing a year-on-year growth of 9.84%, while the net profit attributable to the parent company was -125 million CNY, showing a 47.25% increase year-on-year [2]. - As of June 30, the number of Baiotai's shareholders increased by 11.20% to 9,481, while the average circulating shares per person decreased by 10.07% to 43,674 shares [2].